3/20 #TumorBoardTuesday

💡Mini tweetorial 2

2.📚ARASENS trial
ADT + doce vs ADT + doce + darolutamide 
Including both low and high burden of disease
Median OS: 48.9 months w/o daro vs Not Reached w/ daro 🏆
#TumorBoardTuesday